General Information of Drug (ID: DMXD0C3)

Drug Name
ADS-102891 Drug Info
Synonyms ADS-102891; CHEMBL424728; SCHEMBL6508765; BDBM50200792
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11189610
TTD Drug ID
DMXD0C3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-830216 DMCW71N Obesity 5B81 Phase 1 [2]
AZD1979 DMQ1OX4 Obesity 5B81 Phase 1 [3]
PMID25522065-Compound-27 DMXN4KB N. A. N. A. Patented [4]
PMID25522065-Compound-29 DMBNAK9 N. A. N. A. Patented [4]
PMID25522065-Compound-34 DMZDIRQ N. A. N. A. Patented [4]
PMID25522065-Compound-39 DM5YMQH N. A. N. A. Patented [4]
PMID25522065-Compound-40 DMCIQ01 N. A. N. A. Patented [4]
PMID25522065-Compound-11 DM410Z6 N. A. N. A. Patented [4]
PMID25522065-Compound-50 DMBWA0V N. A. N. A. Patented [4]
PMID25522065-Compound-12 DMVKO9C N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanin-concentrating hormone receptor 1 (MCHR1) TTX4RTB MCHR1_HUMAN Inhibitor [1]

References

1 Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
2 2011 Pipeline of Bristol-Myers Squibb.
3 Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc
4 Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.